Roche announced that a Phase III trial showed its immunotherapy Tecentriq plus the chemotherapy Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer.
The drugmaker’s IMpassion130 study aimed to demonstrate a statistically significant improvement in progression-free survival in key patient groups, including the conservative intention-to-treat population.
Patients with triple-negative breast cancer have tumors that do not respond to hormone therapy so there is significant interest in finding new, better ways to tackle this form of the disease.
“Highly encouraged by these results, we plan to submit to health authorities globally with the aim of bringing this combination to people with triple negative breast cancer as soon as possible,” Roche Chief Medical Officer Sandra Horning.
Read the Reuter's coverage